Drug intelligence / Profile preview

GSKVX000000034798

Development stage: Phase 2
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

**GSKVX000000034798** is a GSK investigational **mRNA-based multivalent seasonal influenza vaccine candidate**. It is being evaluated for prevention of influenza by inducing vaccine-directed humoral immune responses, while assessing safety and reactogenicity in adult populations. The exact encoded antigen composition, valency, formulation assignment, adjuvant use, and licensed product name have not been publicly identified.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on GSKVX000000034798.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSKVX000000034798.